Condition: Erythema Nodosum Leprosum · Sponsor: Medicines Development for Global Health
Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Harborview Medical Center, University of Washington | Seattle, Washington, United States | Not Yet Recruiting |
| Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli | Abomey-Calavi, Benin | Not Yet Recruiting |
| Chr de Divo | Divo, Côte d’Ivoire | Not Yet Recruiting |
| Universitas Gadjah Mada | Yogyakarta, Indonesia | Not Yet Recruiting |
| Programme national lutte contre la lèpre | Tôlanaro, Madagascar | Not Yet Recruiting |
| Philippine General Hospital, University of the Philippines, Manila | Manila, Philippines | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07172659